-

08:45:01 PM

ABBV Stock News

ABBV - Abbvie Inc

11/23/22 8:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the Evercore ISI HealthCONx Conference

AbbVie (NYSE: ABBV) will participate in the 5 th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott

RHEA-AI

neutral

11/23/22 2:00 AM

NYSE : ABBV

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

- Third approved indication for SKYRIZI ® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) - A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic

RHEA-AI

neutral

11/22/22 3:45 PM

NYSE : ABBV

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

AbbVie (NYSE: ABBV) will present results from

RHEA-AI

neutral

11/22/22 9:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the Piper Sandler Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents,

RHEA-AI

neutral

11/17/22 8:45 AM

NYSE : ABBV

Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet

Yesterday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), celebrated the fourth annual – and most successful – BOTOX ® Cosmetic Day

RHEA-AI

neutral

11/09/22 8:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the Wolfe Research Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 4 th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents,

RHEA-AI

neutral

11/08/22 3:06 PM

NYSE : ABBV

AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022

AbbVie (NYSE: ABBV)

RHEA-AI

neutral

11/07/22 12:31 PM

NYSE : ABBV

clinical trial

AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients

Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients Data showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days compared

RHEA-AI

neutral

11/03/22 8:00 AM

NYSE : ABBV

Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to provide education and

RHEA-AI

neutral

11/02/22 8:00 AM

NYSE : ABBV

Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is inviting people across the country to take a "Moment for You" on

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

ABBV Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.abbvie.com
CeoRichard Gonzalez
Security nameAbbvie Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 N Waukegan Rd
StateIllinois
CityNorth Chicago
Zip60064-1802
CountryUS
Phone18479327900

About Abbvie Inc

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.